



Characterization of β -D- N^4 -Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus

Maryam Ehteshami,^a Sijia Tao,^a Keivan Zandi,^{a,b} Hui-Mien Hsiao,^a Yong Jiang,^a Emily Hammond,^a Franck Amblard,^a Olivia O. Russell,^a Andres Merits,^c Raymond F. Schinazi^a

Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA^a; Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia^b; Institute of Technology, University of Tartu, Tartu, Estonia^c

ABSTRACT Chikungunya virus (CHIKV) represents a reemerging global threat to human health. Recent outbreaks across Asia, Europe, Africa, and the Caribbean have prompted renewed scientific interest in this mosquito-borne alphavirus. There are currently no vaccines against CHIKV, and treatment has been limited to nonspecific antiviral agents, with suboptimal outcomes. Herein, we have identified β -D- N^4 -hydroxycytidine (NHC) as a novel inhibitor of CHIKV. NHC behaves as a pyrimidine ribonucleoside and selectively inhibits CHIKV replication in cell culture.

KEYWORDS Chikungunya virus, replicon, antiviral agents, nucleoside analogs

Chikungunya virus (CHIKV), a mosquito-borne alphavirus, is considered a reemerging threat to global human health. Recent outbreaks in La Reunion, the Caribbean, and Southeast Asia have raised concerns over the control of CHIKV. Changes in mosquito vector spread, global travel, human population growth, and climate change are some of the factors considered to have played a role in the increased incidence and prevalence of CHIKV infection (1, 2). CHIKV infection is associated with an acute febrile phase, followed by a chronic arthralgic phase that can last from weeks to years. In infants, acute chikungunya infection can lead to neuroencephalopathy and lifelong consequences. CHIKV tropism is largely assigned to macrophages and hepatocytes, although infection of other cell types and organs has not been ruled out (3, 4). There are currently no licensed vaccines or antiviral agents with specific mechanisms available for the treatment or prevention of chikungunya virus infection. To date, individuals infected with this virus are treated with broadly acting agents with suboptimal outcomes (5–7). CHIKV has a roughly 11.8-kb RNA genome that codes for four nonstructural and six structural proteins. Nonstructural protein 4 (NSP4), the viral-RNA-dependent RNA polymerase, is essential for synthesis of negative-sense and positive-sense viral RNAs and thus represents an important antiviral drug target (8).

The development of infectious clones and replicon cell lines for CHIKV has facilitated the discovery of small molecules that target specific steps of the viral replication cycle. To date, several studies have identified small-molecule inhibitors that inhibit CHIKV replication in cell culture (9–14). Some nucleoside analogs, such as ribavirin, have also been shown to interfere with CHIKV replication. Ribavirin is a broadly acting agent used for the treatment of other viral infections, such as hepatitis C (15). More recently, favipiravir, an effective antiviral agent against several RNA viruses, was reported to inhibit CHIKV replication *in vitro* (12). Interestingly, it was shown that favipiravir selected for resistance-associated mutations in NSP4. Although this suggests that NSP4 is the

Received 15 November 2016 Returned for modification 5 December 2016 Accepted 23 January 2017

Accepted manuscript posted online 30 January 2017

Citation Ehteshami M, Tao S, Zandi K, Hsiao H-M, Jiang Y, Hammond E, Amblard F, Russell OO, Merits A, Schinazi RF. 2017. Characterization of β -D- N^4 -hydroxycytidine as a novel inhibitor of Chikungunya virus. *Antimicrob Agents Chemother* 61:e02395-16. <https://doi.org/10.1128/AAC.02395-16>.

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Raymond F. Schinazi, rschina@emory.edu.




FIG 1 Evaluation of small molecules for anti-CHIKV activity. (A) Small molecules were evaluated in Huh-7-CHIKV replicon cell culture. A 10 μM concentration of each compound was incubated with 5,000 cells/well in triplicate 96-well plates for 48 h at 37°C. The percent inhibition of the *Renilla* luciferase signal (\pm the standard deviation [SD]) was calculated as normalized to that in no-compound control lanes. The scatter plot represents percent inhibition data for 631 compounds. Only one compound, namely, β -D-*N*⁴-hydroxycytidine (NHC; indicated with a black arrow), was found to inhibit the replicon by over 80%. (B) Chemical structure of the NHC compound.

target of this antiviral agent, the precise mechanism of inhibition remains unknown (12).

In this study, we identify and characterize a nucleoside analog, β -D-*N*⁴-hydroxycytidine (NHC), which has been reported previously by our group to affect hepatitis C virus (16). Herein, we examine the impact of NHC on CHIKV replication in terms of antiviral activity, toxicity, intracellular metabolism, and mechanism of action.

In our search for a nucleoside analog that could inhibit the CHIKV replicon, we evaluated over 600 compounds from our in-house small-molecule library. Compound evaluation was performed in a CHIKV replicon cell culture system essentially as previously described (17). The focused library was prescreened for toxicity, and compounds were evaluated at nontoxic concentrations. Briefly, Huh-7 cells stably transfected with the CHIKV replicon, which harbors a *Renilla* luciferase readout, were seeded at a density of 5,000 cells/well and preincubated at 37°C for 2 h before the addition of a 10 μM concentration of the compound in triplicate. Dimethyl sulfoxide (DMSO) was added as a negative control. The effect of each compound was evaluated after 48 h using a *Renilla* luciferase assay kit (Promega, USA). For dose-response studies, 3-fold dilutions of each compound were added, with the highest concentration being 30 μM . Ribavirin and favipiravir were used as positive controls. The scatter plot depicted in Fig. 1A shows the results of evaluation of the initial compound at 10 μM . We identified the nucleoside analog NHC (Fig. 1B) as a novel anti-CHIKV agent. Further evaluation confirmed that NHC inhibited CHIKV replicon activity and that the 50% effective concentration (EC_{50}) was 0.8 μM in the Huh-7-CHIKV replicon cell line. Similar results were obtained with the replicon in BHK-21 cells (Table 1). This inhibition appeared to be more potent than that of the control nucleoside analogs favipiravir and ribavirin, previously described to have anti-CHIKV activity (12, 17). A continuous-treatment assay was conducted to evaluate

TABLE 1 Anti-CHIKV effect of nucleoside analogs

Compound	EC_{50} (μM) ^c			
	Huh-7-CHIKV replicon	BHK-21-CHIKV replicon	CHIKV infectious model (Asian ^a)	CHIKV infectious model (ECSA ^b)
NHC	0.8 \pm 0.1	1.8 \pm 0.2	0.2	0.2 \pm 0.1
Favipiravir	12.7 \pm 1.6	22.5 \pm 4.7	0.3	0.6
Ribavirin	16.8 \pm 2.2	7.8 \pm 2.2	ND	ND

^aAsian strain CNR20235.

^bECSA strain LR 2006 OPY1.

^cCell-based EC_{50} s are the averages from two to four replicates \pm standard deviations. ND, not determined.




FIG 2 Intracellular metabolism of the parent NHC and the prodrug. Huh-7 cells were incubated with 10 μM (black bars) or 50 μM (white bars) NHC (A) or a McGuigan phosphoramidate prodrug of NHC (B) for 4 h at 37°C. Intracellular levels of the parental compounds and phosphorylated metabolites were measured using LC-MS/MS. Each measurement was repeated in triplicate, and results are means \pm SD. MP, monophosphate; DP, diphosphate; TP, triphosphate.

the antiviral activity of the compound against infectious CHIKV replication in Vero cells (18). Briefly, monolayers of Vero cells were treated with different concentrations of the compound, starting from the maximum nontoxic dose. Concurrently, cells were infected with CHIKV belonging to the East/Central/South African (ECSA) or Asian genotype at a multiplicity of infection (MOI) of 1. After 2 h of incubation, the supernatant was replaced with medium containing the corresponding concentration of inhibitor. The plate was then kept at 37°C and examined daily for the presentation of cytopathic effect. After 48 h, the supernatants were collected and the CHIKV yields were evaluated using quantitative reverse transcription-PCR (q-RT-PCR) as described previously (19). We observed that both CHIKV genotypes were inhibited at similar potencies, with an EC_{50} of 0.2 μM (Table 1). No cytotoxicity was observed for NHC in the Huh-7 cell culture system when we tested NHC at up to 100 μM using standard 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays. The 50% cytotoxic concentration (CC_{50}) values for NHC were determined to be 30.6 μM , 7.7 μM , and 2.5 μM in peripheral blood mononuclear (PBM), Vero, and CEM cells, respectively.

We next evaluated the intracellular metabolism of NHC. We incubated a 10 μM or 50 μM concentration of the NHC parent nucleoside in Huh-7 cells essentially as described previously (20). Briefly, Huh-7 cells were seeded at 1×10^6 cells per well in 12-well plates and incubated with NHC for 4 h. Cells were subsequently washed and analyzed using liquid chromatography-tandem mass spectroscopy (LC-MS/MS). Levels of the parent NHC, along with each of the 5'-mono-, di-, and triphosphorylated metabolites, were measured. Under these conditions, small amounts of NHC-monophosphate (MP) and NHC-diphosphate (DP) were observed, while NHC-triphosphate (TP) remained the most abundant metabolite (Fig. 2A). It is worth noting that at 10 μM , the synthesized McGuigan phosphoramidate prodrug of NHC showed only low levels of inhibition (<30%) in CHIKV replicon cell experiments. LC-MS/MS assays revealed that compared to the parent NHC, the prodrug NHC produced far lower levels of all detected metabolites (Fig. 2B). Specifically, incubation of 10 μM parent NHC generated 355 pmol/million cells of NHC-TP, while incubation of 10 μM prodrug NHC generated




FIG 3 Effect of exogenous nucleosides on NHC-mediated inhibition of the CHIKV replicon. (A) Schematic representation of the experimental layout. Huh-7-CHIKV replicon cells were incubated for 48 h with 1 μ M NHC and increasing concentrations of exogenous ribonucleosides (B, top panel) or 2'-deoxyribonucleosides or thymidine (B, bottom panel). Percent inhibition was normalized to 100% in the presence of 1 μ M NHC alone. The x axis represents the nucleoside concentration gradient. The y axis represents percent inhibition of the CHIKV replicon as measured via *Renilla* luciferase activity. Each experiment was repeated in triplicate, and results are means \pm SD.

30 pmol/million cells (an \sim 12-fold difference). Incubation of 50 μ M parent NHC generated 1,100 pmol/million cells of NHC-TP, while incubation of 50 μ M prodrug NHC generated 130 pmol/million cells (an \sim 8-fold difference) (Fig. 2).

In order to shed light on the mechanism of action of NHC, we next evaluated whether NHC-mediated inhibition of the CHIKV replicon could be abrogated by the addition of exogenous nucleosides. Huh-7-CHIKV replicon cells were treated with 1 μ M NHC together with 0 to 100 μ M adenosine (A), cytidine (C), guanosine (G), uracil (U), 2'-deoxyadenosine (dA), 2'-deoxycytidine (dC), 2'-deoxyguanosine (dG), 2'-deoxyuridine (dU), or thymidine (T) (Fig. 3A). Percent inhibition in the presence of exogenous nucleosides was normalized to that of the sample containing 1 μ M NHC alone (representing 100% inhibition) and to the no-NHC and no-nucleoside negative controls (representing 0% inhibition). We observed that the addition of dA, dC, dG, dU, or T had no impact on the replicon (Fig. 3B, lower panel), while the addition of pyrimidines C and U abrogated inhibition (Fig. 3B, top panel). These data suggest that NHC behaves as a pyrimidine analog, considering that its inhibition could be either directly or indirectly abrogated only with the addition of natural pyrimidine ribonucleosides. Finally, we noted that A and G contributed to replicon inhibition both in the presence and in the absence of NHC (Fig. 3B and data not shown), presumably by affecting cell viability. This observation was consistent with those of previous reports in other cell settings with regard to the impact of exogenous G or A on the induction of apoptosis (21, 22).

Finally, a time-of-addition experiment using infectious CHIKV (Asian genotype) was performed essentially as previously described (23, 24). Briefly, 0.3 μ M NHC was added to Vero cell monolayers before, at the same time, or at various time points after virus infection at an MOI of 1; the compound was present until samples were harvested at 48 h postinfection. Virus yield was measured as described above. We observed that the highest level of inhibition occurred when NHC was added before virus infection; however, high levels of inhibition were sustained up to an additional 2 h postinoculation (Fig. 4). In contrast, when NHC was added at 4 h postinfection or later, only \sim 20% inhibition was observed. Combined, our data suggest that NHC has little or no effect on CHIKV entry; instead, it acts as an early-stage inhibitor of CHIKV replication.




FIG 4 Time-of-addition assay for the NHC compound. Vero cells were treated with $0.3 \mu\text{M}$ NHC either before, at the same time (time zero), or after CHIKV infection at an MOI of 1. A virus yield reduction assay was subsequently performed to determine percent inhibition of virus production. Each time point measurement was repeated in triplicate, and results are means \pm SD.

Herein, we have characterized NHC as a novel inhibitor of CHIKV through replicon- and infectious-virus-based assays. Although the precise mechanism of action of this pyrimidine analog remains to be determined, our data allow us to speculate on several possible inhibitory pathways. Considering its high intracellular levels, the NHC-TP metabolite may directly target the viral polymerase and behave as a nonobligate chain terminator. Alternatively, NHC-TP incorporation into viral RNA may result in an increased rate of mutagenesis (25, 26). Inhibitory activity in the replicon cell line indicates that NHC is not an entry inhibitor, while time-of-addition experiments suggest that NHC inhibits the early phase of CHIKV replication. Together, these data suggest that NHC-TP may play a prominent role in inhibiting early negative-strand RNA synthesis, either through chain termination or mutagenesis, which may in turn interfere with correct replicase complex formation. In conclusion, here we have described the inhibition of CHIKV replication by NHC, a novel nucleoside analog not previously implicated in alphavirus inhibition. This study sheds light on and guides the future development of antivirals against CHIKV. Moreover, NHC can be used as a positive control for drug discovery of more-potent and -selective anti-CHIKV agents.

ACKNOWLEDGMENTS

This work was supported in part by NIH grants 5P30-AI-50409 (to R.F.S.) (Center for AIDS Research) and 1R21-AI-129607.

REFERENCES

- Lo Presti A, Cella E, Angeletti S, Ciccozzi M. 2016. Molecular epidemiology, evolution and phylogeny of Chikungunya virus: an updating review. *Infect Genet Evol* 41:270–278. <https://doi.org/10.1016/j.meegid.2016.04.006>.
- Madariaga M, Ticona E, Resurrecion C. 2016. Chikungunya: bending over the Americas and the rest of the world. *Braz J Infect Dis* 20:91–98. <https://doi.org/10.1016/j.bjid.2015.10.004>.
- van Duijl-Richter MK, Hoorweg TE, Rodenhuis-Zybert IA, Smit JM. 2015. Early events in Chikungunya virus infection—from virus cell binding to membrane fusion. *Viruses* 7:3647–3674. <https://doi.org/10.3390/v7072792>.
- Couderc T, Lecuit M. 2015. Chikungunya virus pathogenesis: from bedside to bench. *Antiviral Res* 121:120–131. <https://doi.org/10.1016/j.antiviral.2015.07.002>.
- Abdelnabi R, Neyts J, Delang L. 2015. Towards antivirals against chikungunya virus. *Antiviral Res* 121:59–68. <https://doi.org/10.1016/j.antiviral.2015.06.017>.
- Salazar-Gonzalez JA, Angulo C, Rosales-Mendoza S. 2015. Chikungunya virus vaccines: current strategies and prospects for developing plant-made vaccines. *Vaccine* 33:3650–3658. <https://doi.org/10.1016/j.vaccine.2015.05.104>.
- McSweeney E, Weaver SC, Lecuit M, Frieman M, Morrison TE, Hrynokow S. 2015. The Global Virus Network: challenging chikungunya. *Antiviral Res* 120:147–152. <https://doi.org/10.1016/j.antiviral.2015.06.003>.
- Thiboutot MM, Kannan S, Kawalekar OU, Shedlock DJ, Khan AS, Sarangan G, Srikanth P, Weiner DB, Muthumani K. 2010. Chikungunya: a potentially emerging epidemic? *PLoS Negl Trop Dis* 4:e623. <https://doi.org/10.1371/journal.pntd.0000623>.
- Henss L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle BS. 2016. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. *Virology* 13:149. <https://doi.org/10.1186/s12985-016-0607-2>.
- Karlas A, Berre S, Couderc T, Varjak M, Braun P, Meyer M, Gangneux N, Karo-Astover L, Weege F, Raftery M, Schonrich G, Klemm U, Wurzbauer A, Bracher F, Merits A, Meyer TF, Lecuit M. 2016. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. *Nat Commun* 7:11320. <https://doi.org/10.1038/ncomms11320>.
- Albulescu IC, van Hoolwerff M, Wolters LA, Bottaro E, Nastruzzi C, Yang SC, Tsay SC, Hwu JR, Snijder EJ, van Hemert MJ. 2015. Suramin inhibits chikungunya virus replication through multiple mechanisms. *Antiviral Res* 121:39–46. <https://doi.org/10.1016/j.antiviral.2015.06.013>.
- Delang L, Segura Guerrero N, Tas A, Querat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie

- X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. *J Antimicrob Chemother* 69: 2770–2784. <https://doi.org/10.1093/jac/dku209>.
13. Bourjot M, Leyssen P, Neyts J, Dumontet V, Litaudon M. 2014. Trigocherierin A, a potent inhibitor of chikungunya virus replication. *Molecules* 19:3617–3627. <https://doi.org/10.3390/molecules19033617>.
 14. Das PK PL, Varghese FS, Utt A, Ahola T, Kananovich DG, Lopp M, Merits A, Karelson M. 2016. Design and validation of novel chikungunya virus protease inhibitors. *Antimicrob Agents Chemother* 60:7382–7395. <https://doi.org/10.1128/AAC.01421-16>.
 15. Ravichandran R, Manian M. 2008. Ribavirin therapy for Chikungunya arthritis. *J Infect Dev Ctries* 2:140–142. <https://doi.org/10.3855/TJ.2.140>.
 16. Hernandez-Santiago BI, Beltran T, Stuyver L, Chu CK, Schinazi RF. 2004. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. *Antimicrob Agents Chemother* 48:4636–4642. <https://doi.org/10.1128/AAC.48.12.4636-4642.2004>.
 17. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, Tammela P. 2011. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. *PLoS One* 6:e28923. <https://doi.org/10.1371/journal.pone.0028923>.
 18. Lani R, Hassandarvish P, Chiam CW, Moghaddam E, Chu JJ, Rausalu K, Merits A, Higgs S, Vanlandingham D, Abu Bakar S, Zandi K. 2015. Antiviral activity of silymarin against chikungunya virus. *Sci Rep* 5:11421. <https://doi.org/10.1038/srep11421>.
 19. Chiam CW, Chan YF, Loong SK, Yong SS, Hooi PS, Sam IC. 2013. Real-time polymerase chain reaction for diagnosis and quantitation of negative strand of chikungunya virus. *Diagn Microbiol Infect Dis* 77:133–137. <https://doi.org/10.1016/j.diagmicrobio.2013.06.018>.
 20. Ehteshami M, Tao S, Ozturk T, Zhou L, Cho JH, Zhang H, Amiralei S, Shelton JR, Lu X, Khalil A, Domaal RA, Stanton RA, Suesserma JE, Lin B, Lee SS, Amblard F, Whitaker T, Coats SJ, Schinazi RF. 2016. Biochemical characterization of the active anti-hepatitis C virus metabolites of 2,6-diaminopurine ribonucleoside prodrug compared to sofosbuvir and BMS-986094. *Antimicrob Agents Chemother* 60: 4659–4669. <https://doi.org/10.1128/AAC.00318-16>.
 21. Han Z, Wyche JH. 1994. Guanosine induces necrosis of cultured aortic endothelial cells. *Am J Pathol* 145:423–427.
 22. Wu LF, Li GP, Feng JL, Pu ZJ. 2006. Molecular mechanisms of adenosine-induced apoptosis in human HepG2 cells. *Acta Pharmacol Sin* 27: 477–484. <https://doi.org/10.1111/j.1745-7254.2006.00302.x>.
 23. Varghese FS, Rausalu K, Hakanen M, Saul S, Kummerer BM, Susi P, Merits A, Ahola T. 19 December 2016. Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments. *Antimicrob Agents Chemother* <https://doi.org/10.1128/AAC.02227-16>.
 24. Ahmadi A, Hassandarvish P, Lani R, Yadollahi P, Jokar A, Bakar SA, Zandi K. 2016. Inhibition of chikungunya virus replication by hesperetin and naringenin. *RSC Adv* 6:69421–69430. <https://doi.org/10.1039/C6RA16640G>.
 25. Sledziewska-Gojska E, Janion C. 1983. Do DNA repair systems affect N4-hydroxycytidine-induced mutagenesis? *Acta Biochim Pol* 30: 149–157.
 26. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. *Antimicrob Agents Chemother* 47:244–254. <https://doi.org/10.1128/AAC.47.1.244-254.2003>.